The company has a strong cash position of $471m, despite a net loss of $63m in 2024, providing a long funding runway. Click ...

A school administrator who has been suffering topical steroid withdrawal (TSW) says she feels helpless after five years of ...

Sanofi signed a deal with Earendil Labs for $125 million upfront and $1.72 billion in milestone payments. Regeneron Pharmaceuticals signed a deal worth more than $3 billion with contract drug ...

“Steroid withdrawal has had a massive impact on my life ... Fortunately, there are eczema treatment alternatives to steroid creams. Interleukin (Dupixent) and JAK (Rinvoq) inhibitors are excellent ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria (“CSU”) in adults and adolescents aged 12 years ...

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria. The approval is for patients 12 years and ...

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and ...